Concepedia

Author

Asher Chanan‐Khan

Mayo Clinic in FloridaORCID

Also Known As

A A Chanan-Khan, A CHANANKHAN, A Chanan-Khan, A. A. Chanan-Khan, A. Chanan-Khan, A. Chanan‐Khan, A.A. Chanan-Khan, Asher A Chanan-Khan, Asher A. Chanan-Khan, Asher A. Chanan‐Khan

658

Publications

21.3K

Citations

69

H-Index

137

Concepts

All Affiliations

Mayo Clinic in FloridaRoswell Park Comprehensive Cancer CenterWinnMedMayo Clinic in ArizonaJacksonville College
AC

About

Asher Chanan‐Khan is an author at Mayo Clinic in Florida specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

35

68

5.2K

2

Health Sciences

19

30

1.4K

3

Public Health

9

9

618

4

Education

1

1

17

5

Natural Sciences

1

1

76

Asher Chanan‐Khan

×

213

Publications

17.6K

Citations

63

H-Index

YearCitations

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel,

New England Journal of Medicine

2016

1.5K

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Donna M. Weber, Christine Chen, Rubén Niesvizky,

New England Journal of Medicine

2007

1.2K

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees,

Blood

2007

762

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang,

Blood

2012

654

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Joseph Mıkhael, David Dingli, Vivek Roy,

Mayo Clinic Proceedings

2013

485

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

Asher Chanan‐Khan, János Szebeni, Sándor Sávay,

Annals of Oncology

2003

460

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

Meletios Α. Dimopoulos, Robert A. Kyle, Jean-Paul Fermand,

Blood

2011

448

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call,

Blood

2017

411

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Asher Chanan‐Khan, Kena C. Miller, Laurie Musial,

Journal of Clinical Oncology

2006

408

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan,

The Lancet Oncology

2015

408

Page 1